Mechanisms and consequences of hypertriglyceridemia and cellular lipid accumulation in chronic kidney disease and metabolic syndrome

Histology and Histopathology

Volumn 26, Issue 12, 2011, Pages 1599-1610

  Lee, Hyun Soon ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

Free fatty acids; Glomerulosclerosis; Lipogenesis; Lipolysis; Lipotoxicity

Indexed keywords

FATTY ACID; LIPOPROTEIN; TRIACYLGLYCEROL;

CHRONIC DISEASE; HOMEOSTASIS; HUMAN; HYPERTRIGLYCERIDEMIA; KIDNEY; KIDNEY DISEASE; LIPID METABOLISM; METABOLIC SYNDROME X; METABOLISM; PATHOLOGY; REVIEW;

CHRONIC DISEASE; FATTY ACIDS; HOMEOSTASIS; HUMANS; HYPERTRIGLYCERIDEMIA; KIDNEY; KIDNEY DISEASES; LIPID METABOLISM; LIPOPROTEINS; METABOLIC SYNDROME X; TRIGLYCERIDES;

EID: 80053981434     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (119)

1. Abrass C.K. (2004). Cellular lipid metabolism and the role of lipids in progressive renal disease. Am. J. Nephrol. 24, 46-53.
2. Ahima R.S. and Flier J.S. (2000). Leptin. Annu. Rev. Physiol. 62, 413-437.
3. Alberti K.G.M.M., Zimmet P. and Shaw J. (2006). Metabolic syndrome-a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet. Med. 23, 469-480.
4. Arnandottir M., Thysell H., Dallongeville J., Fruchart J.-C. and Nilsson-Ehle P. (1995). Evidence that reduced lipoprotein lipase activity is not a primary pathogenetic factor for hypertriglyceridemia in renal failure. Kidney Int. 48, 779-784.
5. Attman P.O., Samuelson O. and Alaupovic P. (1993). Lipoprotein metabolism in renal failure. Am. J. Kidney Dis. 21, 573-592.
6. Bagby S.P. (2004). Obesity-initiated metabolic syndrome and the kidney: A recipe for chronic kidney disease? J. Am. Soc. Nephrol. 15, 2775-2791.
7. Baker A.D., Malur A., Barna B.P., Kavuru M.S., Malur A.G. and Thomassen M.J. (2010). PPAR-TTregulates the expression of cholesterol metabolism genes in alveolar macrophages. Biochem. Biophys. Res. Commun. 393, 682-687.
8. Baranowski M. (2008). Biological role of liver X receptors. J. Physiol. Pharmacol. 59 (suppl 7), 31-55.
9. Barista M.C., Wellty F.K., Diffenderfer M.R., Sarnak M.J., Schaefer E.J., Lamon-Fava S., Asztalos B.F., Dolnikowski G.G., Brousseau M.E. and Marsh J.B. (2004). Apolipoprotein A-1, B-100, and B-48 metabolism in subjects with chronic kidney disease, obesity, and the metabolic syndrome. Metabolism 53, 1255-1261.
10. Barrett P.H.R. and Watts C.F. (2003). Kinetic studies of lipoprotein metabolism in the metabolic syndrome including effects of nutritional interventions. Curr. Opin. Lipidol. 14, 61-68.
11. Bartlett K. and Eaton S. (2004). Mitochondrial ß-oxidation. Eur. J. Biochem. 271, 462-469.
12. Berfield A.K. and Abrass C.K. (2002). IGF-1 induces foam cell formation in rat glomerular mesangial cells. J. Histochem. Cytochem. 50, 395-403.
13. Berfield A.K., Chait A., Oram J.F., Zager R.A., Johnson A.C. and Abrass C.K. (2006). IGF-1 induces rat glomerular mesangial cells to accumulate triglyceride. Am. J. Physiol. Renal Physiol. 290, F138-F147.
14. Berneis K., Rizzo M., Spinas G.A., Di Lorenzo G., Di Fede G., Pepe I., Pernice V. and Rini G.B. (2009). The predictive role of atherogenic dyslipidemia in subjects with non-coronary atherosclerosis. Clin. Chim. Acta 406, 36-40.
15. Brown M.S. and Goldstein J.L. (1997). The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89, 331-340.
16. Chen J., Muntner P., Hamm L.L., Jones D.W., Batuman V., Fonseca V., Whelton P.K. and He J. (2004). The metabolic syndrome and chronic kidney disease in US adults. Ann. Intern. Med. 140, 167-174.
17. Chen Y., Ruan X.Z., Li Q., Huang A., Moorhead J.F., Powis S.H. and Varghese Z. (2007). Inflammatory cytokines disrupt LDL-receptor feedback regulation and cause statin resistance: a comparative study in human hepatic cells and mesangial cells. Am. J. Physiol. Renal Physiol. 293, F680-F687.
18. Cohn J.S., Marcoux C. and Davignon J. (1995). Detection, quantification, and characterization of potentially atherogenic triglyceride-rich remnant lipoproteins. Arterioscler. Thromb. Vasc. Biol. 19, 2474-2486.
19. Coimbra T.M., Janssen U., Gröne H.J., Ostendorf T., Kunter U., Schmidt H., Brabant G. and Floege J. (2000). Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetes. Kidney Int. 57, 167-182.
20. Davies R.W., Staprans I., Hutchison F.N. and Kaysen G.A. (1990). Proteinuria, not altered albumin metabolism, affects hyperlipidemia in the nephrotic rat. J. Clin. Invest. 86, 600-605.
21. Deb D.K., Sun T., Wong K.E., Zhang Z., Ning G., Zhang Y., Kong J., Shi H., Chang A. and Li Y.C. (2010). Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes. Kidney Int. 77, 1000-1009.
22. Deboer M.D., Zhu X., Levasseur P.R., Inui A., Hu Z., Han G., Mitch W.E., Taylor J.E., Halem H.A., Dong J.Z., Datta R., Culler M.D. and Marks D.L. (2008). Ghrelin treatment of chronic kidney disease: improvements in lean body mass and cytokine profile. Endocrinology 149, 827-835.
23. Dergunov A.D., Smirnova E.A., Merched A., Visvikis S., Siest G., Yakushkin W. and Tsibulsky V. (2000). Structural peculiarities of the binding of very low density lipoproteins and low density lipoproteins to the LDL receptor in hypertriglyceridemia: role of apolipoprotein E. Biochim. Biophys. Acta 1484, 29-40.
24. de Sain-van der Velden M.G., Kaysen G.A., Barrett H.A., Stellaard F., Gadellaa M.M., Voorbij H.A., Reijngoud D.J. and Rabelink T.J. (1998). Increased VLDL in nephrotic patients results from a decreased catabolism while increased LDL results from increased synthesis. Kidney Int. 53, 994-1001.
25. Doege H. and Stahl A. (2006). Protein-mediated fatty acid uptake: novel insights from in vivo models. Physiology (Bethesda) 21, 259-268.
26. Farooqi I.S., Wangensteen T., Collins S., Kimber W., Matarese G., Keogh J.M., Lank E., Bottomley B., Lopez-Fernandez J., Ferraz-Amaro I., Dattani M.T., Ercan O., Myhre A.G., Retterstol L., Stanhope R., Edge J.A., McKenzie S., Lessan N., Ghodsi M., De Rosa V., Perna F., Fontana S., Barroso I., Undlien D.E. and O'Rahiilly S. (2007). Clinical and molecular genetic spectrum of congenital deficiency of the leptin receptor. N. Engl. J. Med. 356, 237-247.
27. Fogo A.B. (2011). PPARFFand chronic kidney disease. Pediatr. Nephrol. 26, 347-351.
28. Frykman P.K., Brown M.S., Yamamoto T., Goldstein J.L. and Herz J. (1995). Normal plasma lipoproteins and fertility in gene-targeted mice homozygous for a disruption in the gene encoding very low density lipoprotein receptor. Proc. Natl. Acad. Sci. USA 92, 8453-8457.
29. Furukawa S., Hirano T., Mamo J.C., Nagano S. and Takahashi T. (1990). Catabolic defect of triglyceride is associated with abnormal very-low-density lipoprotein in experimental nephrosis. Metabolism 39, 101-107.
30. Gassler N., Elger M., Kränzlin B., Kriz W., Gretz N., Hähnel B.H., Hosser H. and Hartmann I. (2001). Podocyte injury underlies the progression of focal segmental glomerulosclerosis in the fa/fa Zucker rat. Kidney Int. 60, 106-116.
31. Gillian-Daniel D.L., Bates P.W., Tebon A. and Attie A.D. (2002). Endoplasmic reticulum localization of the low density lipoprotein receptor mediates presecretory degradation of apolipoprotein B. Proc. Natl. Acad. Sci. USA 99, 4337-4342.
32. Goudriaan J.R., Espirito Santo S.M., Voshol P.J., Teusink B., van Dijk K.W., van Vlijmen B.J., Romijn J.A., Havekes L.M. and Rensen P.C. (2004). The VLDL receptor plays a major role in chylomicron metabolism by enhancing LPL-mediated triglyceride hydrolysis. J. Lipid Res. 45, 1475-1481.
33. Goudriaan J.R., Tacken P.J., Dahlmans V.E., Gijbels M.J., van Dijk K.W., Havekes L.M. and Jong M.C. (2001). Protection from obesity in mice lacking the VLDL receptor. Arterioscler. Thromb. Vasc. Biol. 21, 1488-1493.
34. Guan Y. (2004). Peroxisome proliferator-activated receptor family and its relationship to renal complications of the metabolic syndrome. J. Am. Soc. Nephrol. 15, 2801-2815.
35. Hagberg C.E., Falkevall A., Wang X., Larsson E., Huusko J., Nilsson I., van Meeteren L.A., Samen E., Lu L., Vanwildemeersch M., Klar J., Genove G., Pietras K., Stone-Elander S., Claesson-Welsh L., Ylä-Herttuala S., Lindahl P. and Eriksson U. (2010). Vascular endothelial growth factor B controls endothelial fatty acid uptake. Nature 46, 917-921.
36. Henique C., Mansouri A., Fumey G., Lenoir V., Girard J., Bouillaud F., Prip-Buus C. and Cohen I. (2010). Increased mitochondrial fatty acid oxidation is sufficient to protect skeletal muscle cells from palmitateinduced apoptosis. J. Biol. Chem. 285, 36818-36827.
37. Hirano T., Ebara T., Furukawa S., Nagano S. and Takahashi T. (1994). Mechanism of hypertriglyceridemia in Dahl salt-sensitive rats, an animal model of spontaneous nephrotic syndrome. Metabolism 42, 248-256.
38. Hong C., Duit S., Jalonen P., Out R., Scheer L., Sorrentino V., Boyadjian R., Rodenburg K.W., Foley E., Korhonen L., Lindholm D., Nimpf J., van Berkel T.J., Tontonoz P. and Zelcer N. (2010). The E3 ubiquitin ligase IDOL induces the degradation of the low density lipoprotein receptor family members VLDLR and ApoER2. J. Biol. Chem. 285, 19720-19726.
39. Horton J.D., Goldstein J.L. and Brown M.S. (2002). SREBPs: Activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest. 109, 1125-1131.
40. Huang Z.H., Minshall R.D. and Mazzone T. (2009). Mechanism for endogenously expressed apoE modulation of adipocyte very low density lipoprotein metabolism. Role in endocytic and lipasemediated metabolic pathways. J. Biol. Chem. 284, 31512-31522.
41. Iida M., Murakami T., Ishida K., Mizuno A., Kuwajima M. and Shima K. (1996). Phenotype-linked amino acid alteration in leptin receptor cDNA from Zucker fatty (fa/fa) rat. Biochem. Biophys. Res. Commun. 222, 19-26.
42. Jiang T., Wang Z., Proctor G., Moskowitz S., Liebman S., Rogers T., Lucia M.S., Li J. and Levi M. (2005). Diet-induced obesity in C57BL/6J mice causes increased renal lipid accumulation and glomerulosclerosis via a sterol regulatory element-binding protein-1c-dependent pathway. J. Biol. Chem. 280, 32317-32325.
43. Johnson A.C.M., Yabu J.M., Hanson S., Shah V.O. and Zager R.A. (2003). Experimental glomerulopathy alters renal cortical cholesterol, SR-B1, ABCA1, and HMG CoA reductase expression. Am. J. Pathol. 162, 283-291.
44. Joles J.A., van Goor H., van der Horst M.L.C., van Tol A., Elema J.D. and Koomans H.A. (1995). High lipid levels in very low density lipoprotein and intermediate density lipoprotein may cause proteinuria and glomerulosclerosis in aging female analbumic rats. Lab. Invest. 73, 912-921.
45. Joles J.A., Kunter U., Janssen U., Kriz W., Rabelink T.J., Koomans H.A. and Floege J. (2000). Early mechanisms of renal injury in hypercholesterolemic or hypertriglyceridemic rats. J. Am. Soc. Nephrol. 11, 669-683.
46. Kambham N., Markowitz G., Valeri A.M., Lin J. and D'Agati V. (2001). Obesity-related glomerulopathy: an emerging epidemic. Kidney Int. 59, 1498-1509.
47. Karmi A., Iozzo P., Viljanen A., Hirvonen J., Fielding B.A., Virtanen K., Oikonen V., Kemppainen J., Viljanen T., Guiducci L., Haaparanta-Solin M., Någren K., Solin O. and Nuutila P. (2010). Increased brain fatty acid uptake in metabolic syndrome. Diabetes 59, 2171-2177.
48. Keane W.F. (2000). The role of lipids in renal disease: Future challenges. Kidney Int. 57(suppl 75), S27-S31.
49. Kerner J. and Hoppel C. (2000). Fatty acid import into mitochondria. Biochim. Biophys. Acta 1486, 1-17.
50. Kim H.J., Moradi H., Yuan J., Norris K. and Vaziri N.D. (2009). Renal mass reduction results in accumulation of lipids and dysregulation of lipid regulatory proteins in the remnant kidney. Am. J. Physiol. Renal Physiol. 296, F1297-F1306.
51. Korczyska J., Stelmanska E., Nogalska A., Szolkiewicz M., Goyke E., Swierczynski J. and Rutkowski B. (2004). Upregulation of lipogenic enzymes genes expression in white adipose tissue of rats with chronic renal failure is associated with higher level of sterol regulatory element binding protein-1. Metabolism 53, 1060-1065.
52. Kume S., Uzu T., Araki S.-i., Sugimoto T., Isshiki K., Chin-Kanasaki M., Sakaguchi M., Kubota N., Terauchi Y., Kadowaki T., Haneda M., Kashiwagi A. and Koya D. (2007). Role of altered renal lipid metabolism in the development of renal injury induced by a high-fat diet. J. Am. Soc. Nephrol. 18, 2715-2723.
53. Lee G.H., Proenca R., Montez J.M., Carroll K.M., Darvishzadeh J.G., Lee J.I. and Friedman J.M. (1996). Abnormal splicing of the leptin receptor in diabetic mice. Nature 379, 632-635.
54. Lee H.S. and Lee S.K. (1993). Intraglomerular lipid deposition in renal disease. Miner. Electrolyte Metab. 19, 144-148.
55. Lee H.S. and Kim Y.S. (1998). Identification of oxidized LDL in human renal biopsies. Kidney Int. 54, 848-856.
56. Lee H.S. and Koh H.I. (1994). Visualization of binding and uptake of oxidized low density lipoproteins by cultured mesangial cells. Lab. Invest. 71, 200-208.
57. Lee H.S. and Song C.Y. (2009). Oxidized low-density lipoprotein and oxidative stress in the development of glomerulosclerosis. Am. J. Nephrol. 29, 62-70.
58. Lee H.S. and Song C.Y. (2010). Effects of TGF-ß on podocyte growth and disease progression in proliferative podocytopathies. Kidney Blood Press. Res. 33, 24-29.
59. Lee H.S., Lee J.S., Koh H.I. and Ko K.W. (1991). Intraglomerular lipid deposition in routine biopsies. Clin. Nephrol. 36, 67-75.
60. Lee H.S., Jeong J.Y., Kim B.C., Kim Y.S., Zhang Y.Z. and Chung H.K. (1997). Dietary antioxidant inhibits lipoprotein oxidation and renal injury in experimental focal segmental glomerulosclerosis. Kidney Int. 51, 1151-1159.
61. Lee P.H., Chang H.Y., Tung C.W., Hsu Y.C., Lei C.C., Chang H.H., Yang H.F., Lu L.C., Jong M.C., Chen C.Y., Fang K.Y., Chao Y.S., Shih Y.H. and Lin C.L. (2009). Hypertriglyceridemia: an independent risk factor of chronic kidney disease in Taiwanese adults. Am. J. Med. Sci. 338, 185-189.
62. Lennon R., Pons D., Sabin M.A., Wei C., Shield J.P., Coward R.J., Tavare J.M., Mathieson P.W., Saleem M.A. and Welsh G.I. (2009). Saturated fatty acids induce insulin resistance in human podocytes: implications for diabetic nephropathy. Nephrol. Dial. Transplant. 24, 3286-3296.
63. Liang K. and Vaziri N.D. (1997). Acquired VLDL receptor deficiency in experimental nephrosis. Kidney Int. 51, 1761-1765.
64. Listenberger L.L., Han X., Lewis S.E., Cases S., Farese Jr R.V., Ory D.S. and Schaffer J.E. (2003). Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc. Natl. Acad. Sci. USA 100, 3077-3082.
65. Liu L., Shi X., Bharadwai K.G., Ikeda S., Yamashita H., Yagyu H., Schaeffer J.E., Yu Y.H. and Goldberg I.J. (2009). DGAT1 expression increases heart triglyceride content but ameliorates lipotoxicity. J. Biol. Chem. 284, 36312-36323.
66. Maedler K., Spinas G.A., Dyntar D., Moritz W., Kaiser N. and Donath M.Y. (2001). Distinct effects of saturated and monounsaturated fatty acids on ß-cell turnover and function. Diabetes 50, 69-76.
67. Mancuso D.J., Sims H.F., Yang K., Kiebish M.A., Su X., Jenkins C.M., Guan S., Moon S.H., Pietka T., Nassir F., Schappe T., Moore K., Han X., Abumrad N.A. and Gross R.W. (2010). Genetic ablation of calcium-independent phospholipase A2Á prevents obesity and insulin resistance during high fat feeding by mitochondrial uncoupling and increased adipocyte fatty acid oxidation. J. Biol. Chem. 285, 36495-36510.
68. Masuda D., Hirano K.-i., Oku H., Sandoval J.C., Kawase R., Yuasa-Kawase M., Yamashita Y., Takada M., Tsubakio-Yamamoto K., Tochino Y., Koseki M., Matsuura F., Nishida M., Toshiharu Kawamoto T., Ishigami M., Hori M., Iichiro Shimomura I. and Yamashita S. (2009). Chylomicron remnants are increased in the postprandial state in CD36 deficiency. J. Lipid Res. 50, 999-1011.
69. Mayrhofer C., Krieger S., Huttary N., Chang M.W.-F., Grillari J., Alimaier G. and Kerjaschki D. (2009). Alterations in fatty acid utilization and an impaired antioxidant defense mechanism are early events in podocyte injury. A proteomic analysis. Am. J. Pathol. 174, 1191-1202.
70. Mehta K.D., Chen W.-J., Goldstein J.L. and Brown M.S. (1991). The low density lipoprotein receptor in Xenopus laevis. I. Five domains that resemble the human receptor. J. Biol. Chem. 266, 10406-10414.
71. Mishra R. and Simonson M.S. (2005). Saturated free fatty acids and apoptosis in microvascular mesangial cells: palmitate activates proapoptotic signaling involving caspase 9 and mitochondrial release of endonuclease G. Cardiovasc. Diabetol. 4, 2.
72. Moorhead J.F., Chan M.K., El-Nahas M. and Varghese Z. (1982). Lipid nephrotoxicity in chronic progressive glomerular and tubulointerstitial disease. Lancet 2, 1309-1311.
73. Najafian B., Svarstad E., Bostad L., Gubler M.-C., Tøndel C., Whitley C. and Mauer M. (2011). Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease. Kidney Int. 79, 663-670.
74. Okamura D.M., Lopez-Guisa J.M., Koelsch K., Collins S. and Eddy A.A. (2007). Atherogenic scavenger receptor modulation in the tubulointerstitium in response to chronic renal injury. Am. J. Physiol. Renal Physiol. 293, F575-F85.
75. Oram J.F. and Vaughan A.M. (2006). ATP-binding cassette cholesterol transporters and cardiovascular disease. Circ. Res. 99, 1031-1043.
76. Palanivel R., Eguchi M., Shuralyova I., Coe I. and Sweeney G. (2006). Distinct effects of short-and long-term leptin treatment on glucose and fatty acid uptake and metabolism in HL-1 cardiomyocytes. Metabolism 55, 1067-1075.
77. Phillips M.S., Liu Q., Hammond H.A., Dugan V., Hey P.J., Caskey C.J. and Hess J.F. (1996). Leptin receptor missense mutation in the fatty Zucker rat. (letter) Nat. Genet. 13, 18-19.
78. Praga M., Hernandez E., Morales E., Campos A.P., Valero M.A., Martinez M.A. and Leon M. (2001). Clinical features and long-term outcome of obesity-associated focal segmental glomerulosclerosis. Nephrol. Dial. Transplant. 16, 1790-1798.
79. Ran J., Hirano T. and Adachi M. (2004). Chronic ANG II infusion increases plasma triglyceride level by stimulating hepatic triglyceride production in rats. Am. J. Physiol. Endocrinol. Metab. 287, E955-E961.
80. Rizzo M., Kotur-Stevuljevic J., Berneis K., Spinas G., Rini G.B., Jelic-Ivanovic Z., Spasojevic-Kalimanovska V. and Vekic J. (2009). Atherogenic dyslipidemia and oxidative stress: a new look. Translat. Res. 153, 217-223.
81. Ruan X.Z., Varghese Z., Powis S.H. and Moorhead J.F. (1999). Human mesangial cells express inducible macrophage scavenger receptor. Kidney Int. 56; 440-451.
82. Ruan X.Z., Varghese Z., Powis S.H. and Moorhead J.F. (2001). Dysregulation of LDL receptor under the influence of inflammatory cytokines: A new pathway for foam cell formation. Kidney Int. 60, 1716-1725.
83. Ruan X.Z., Varghese Z. and Moorhead J.F. (2009). An update on the lipid nephrotoxicity hypothesis. Nature Rev. Nephrol. 5, 713-721.
84. Rutkowski B., Szolkiewicz M., Korczyska J., Sucajtys E., Stelmanska E., Nieweglowski T. and Swierczynski J. (2003). The role of lipogenesis in the development of uremic hyperlipidemia. Am. J. Kidney Dis. 41(suppl 1), S84-S88.
85. Rutledge J.C., Ng K.F., Aung H.H. and Wilson D.W. (2010). Role of triglyceride-rich lipoproteins in diabetic nephropathy. Nature Rev. Nephrol. 6, 361-370.
86. Saito K., Ishizaka N., Hara M., Matsuzaki G., Sata M., Mori I., Ohno M. and Nagai R. (2005). Lipid accumulation and transforming growth factor-ß upregulation in the kidneys of rats administered angiotensin II. Hypertension 46, 1180-1185.
87. Samuelsson O., Attman P.-O., Knight-Gibson C., Larsson R., Mulec H., Weiss L. and Alaupovic P. (1998). Complex apolipoprotein Bcontaining lipoprotein particles are associated with a higher rate of progression of human chronic renal insufficiency. J. Am. Soc. Nephrol. 9, 1482-1488.
88. Santamarina-Fojo S. and Haudenschild C. (2000). Role of hepatic and lipoprotein lipase in lipoprotein metabolism and atherosclerosis: studies in transgenic and knockout animal models and somatic gene transfer. Int. J. Tissue React. 22, 39-47.
89. Sato T., Liang K. and Vaziri N.D. (2003). Protein restriction and AST-120 improve lipoprotein lipase and VLDL receptor in focal glomerulosclerosis. Kidney Int. 64, 1780-1786.
90. Schaffer J.E. (2002). Fatty acids transport: the roads taken. Am. J. Physiol. Endocrinol. Metab. 282, E239-E246.
91. Schiffer M., Bitzer M., Roberts I.S.D., Kopp J.B., ten Dijke P., Mundel P. and Böttinger E.P. (2001). Apoptosis in podocytes induced by TGFß and Smad7. J. Clin. Invest. 108, 807-816.
92. Shearer G.C. and Kaysen G.A. (2006). Endothelial bound lipoprotein lipase (LpL) depletion in hypoalbuminemia results from decreased endothelial binding, not decreased secretion. Kidney Int. 70, 647-653.
93. Shearer G.C., Stevenson F.T., Atkinson D.N., Jones Jr H., Staprans I. and Kaysen G.A. (2001). Hypoalbuminemia and proteinuria contribute separately to reduced lipoprotein catabolism in the nephrotic syndrome. Kidney Int. 59, 179-189.
94. Sieber J., Lindenmeyer M.T., Kampe K., Campbell K.N., Cohen C.D., Hopfer H., Mundel P. and Jehle A.W. (2010). Regulation of podocyte survival and endoplasmic reticulum stress by fatty acids. Am. J. Physiol. Renal Physiol. 299, 821-829.
95. Stevenson F.T., Shearer G.C. and Atkinson D.N. (2001). Lipoproteinstimulated mesangial cell proliferation and gene expression are regulated by lipoprotein lipase. Kidney Int. 59, 2062-2068.
96. Sun L., Halaihel N., Zhang W., Rogers T. and Levi M. (2002). Role of sterol regulatory element-binding protein 1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus. J. Biol. Chem. 277, 18919-18927.
97. Syrianen J., Mustonen J. and Pasternack A. (2000). Hypertriglyceridaemia and hyperuricemia are risk factors for progression of IgA nephropathy. Nephrol. Dial. Transplant. 15, 34-42.
98. Szolkiewicz M., Nieweglowski T., Korczyska J., Sucajtys E., Stelmanska E., Goyke E., Swierczynski J. and Rutkowski B. (2002). Upregulation of fatty acid synthase gene expression in experimental chronic renal failure. Metabolism 51, 1605-1610.
99. Takahashi S., Kawarabayasi Y., Nakai T., Sakai J. and Yamamoto T. (1992). Rabbit very low density lipoprotein receptor: A low density lipoprotein receptor-like protein with distinct ligand specificity. Proc. Natl. Acad. Sci. USA 89, 9252-9256.
100. Thomas M.E., Harris K.P.G., Walls J., Furness P.N. and Brunskill N.J. (2002). Fatty acids exacerbate tubulointerstitial injury in proteinoverload proteinuria. Am. J. Physiol. Renal Physiol. 283, F640-F647.
101. Tozawa M., Iseki K., Iseki C., Oshiro S., Ikemiya Y. and Takishita S. (2002). Triglyceride, but not total cholesterol or low-density lipoprotein cholesterol levels, predict development of proteinuria. Kidney Int. 62, 1743-1749.
102. Twisk J., Gillian-Daniel D.L., Tebon A., Wang L., Barrett P.H.R. and Attie A.D. (2000). The role of the LDL receptor in apolipoprotein B secretion. J. Clin. Invest. 105, 521-532.
103. Uchida K. (2000). Role of reactive aldehyde in cardiovascular diseases. Free Radic. Biol. Med. 28, 1685-1696.
104. Unger R.H. (2002). Lipotoxic diseases. Ann. Rev. Med. 53, 319-336.
105. Unger R.H. (2003). Minireview: Weapons of lean body mass destruction: The role of ectopic lipids in the metabolic syndrome. Endocrinology 144, 5159-5165.
106. Unger R.H., Clark G.O., Scherer P.E. and Orci L. (2010). Lipid homeostasis, lipotoxicity and the metabolic syndrome. Biochim. Biophys. Acta 1801, 209-214.
107. Uyeda K. and Repa J.J. (2006). Carbohydrate response element binding protein, ChREBP, a transcription factor coupling hepatic glucose utilization and lipid synthesis. Cell Metab. 4, 107-110.
108. Valbuena C., Oliveira J.P., Carneiro F., Relvas S., Ganhão M., Sá-Miranda M.C. and Rodriques L.G. (2011). Kidney histologic alterations in a-Galactosidase-deficient mice. Virchows Arch. 458, 477-486.
109. van der Vusse G.J., van Bilsen M., Glatz J.F., Hasselbank D.M. and Luiken J.J. (2002). Critical steps in cellular fatty acid uptake and utilization. Mol. Cell Biochem. 239, 9-15.
110. Vaziri N.D. (2006). Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am. J. Physiol. Renal Physiol. 290, F262-272.
111. Vaziri N.D. and Liang K. (1996). Down-regulation of tissue lipoprotein lipase expression in experimental chronic renal failure. Kidney Int. 50, 1928-1935.
112. Weinstock P.H., Levak-Frank S., Hudgins L.C., Radner H., Friedman J.M., Zechner R. and Breslow J.L. (1997). Lipoprotein lipase controls fatty acid entry into adipose tissue, but fat mass is preserved by endogenous synthesis in mice deficient in adipose tissue lipoprotein lipase. Proc. Natl. Acad. Sci. USA 94, 10261-10266.
113. Williams K.J. and Tabas I. (1995). The response-to-retention hypothesis of early atherogenesis. Arterioscler. Thromb. Vasc. Biol. 15, 551-561.
114. Wu Y., Liu Z., Xiang Z., Zeng C., Chen Z., Ma X. and Li L. (2006). Obesity-related glomerulopathy: insights from gene expression profiles of the glomeruli derived from renal biopsy samples. Endocrinology 147, 44-50.
115. Yi F., Jin S., Zhang F., Xia M., Bao J.X., Hu J., Poklis J.L. and Li P.L. (2009). Formation of lipid raft redox signalling platforms in glomerular endothelial cells: an early event of homocysteine-induced glomerular injury. J. Cell Mol. Med. 13, 3303-3314.
116. Yi F., Zhang A.Y., Janscha J.L., Li P.-L. and Zou A.-P. (2004). Homocysteine activates NADH/NADPH oxidase through ceramidestimulated Rac GTPase activity in rat mesangial cells. Kidney Int. 66, 1977-1987.
117. Yoshino G., Hirano T., Nagata K., Maeda E., Naka Y., Murata Y., Kazumi T. and Kasuga M. (1993). Hypertriglyceridemia in nephrotic rats is due to a clearance defect of plasma triglyceride: Overproduction of triglyceride-rich lipoprotein is not an obligatory factor. J. Lipid Res. 34, 875-884.
118. Zhang D.X., Zou A.P. and Li P.L. (2003). Ceramide-induced activation of NADPH oxidase and endothelial cell dysfunction in small coronary arteries. Am. J. Physiol. Heart Circ. Physiol. 284, H605-H612.
119. Zhou Y.-T., Grayburn P., Karim A., Shimabukuro M., Higa M., Baetens D., Orci L. and Unger R.H. (2000). Lipotoxic heart disease in obese rats: implications for human obesity. Proc. Natl. Acad. Sci. USA 97, 1784-1789.